Further, epigenetic mechanisms could also influence the sensitivity of BEV, as demonstrated by Cloughesy et al.‘s finding that methylguanine-DNA methyltransferase (MGMT) methylation may be predictive for onartuzumab (ONA) + BEV outcomes in GBM. This evidence concerns the gene MGMT and glioblastoma.